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ABSTRACT 
Strategies aimed at the lowering of blood ammonia remain the treament of choice in portal-systemic 
encephalopathy (PSE). L-ornithine-L-aspartate (OA) has recently been shown to be effective in the prevention of 
ammonia-precipitated coma in humans with PSE. These findings prompted the study of mechanisms of the 
protective effect of OA in portacaval-shunted rats in which reversible coma was precipitated by ammonium acetate 
administration (3.85 mmol/kg i.p.). OA infusions (300 mg/kg/h, i.v) offered complete protection in 12/12 animals 
compared to 0/12 saline-infused controls. This protective effect was accompanied by significant reductions of blood 
ammonia, concomitant increases of urea production and significant increases in blood and cerebrospinal fluid (CSF) 
glutamate and glutamine. Increased CSF concentrations of leucine and alanine also accompanied the protective 
effect of OA. These findings demonstrate the therapeutic efficacy of OA in the prevention of ammonia-precipitated 
coma in portacaval-shuntedrats and suggest that this protective effect is both peripherally-mediated (increased 
urea and glutamine synthesis) and centrally-mediated (increased glutamine synthesis). 
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INTRODUCTION 
Of the possible neurotoxins implicated in hepatic encephalopathy (HE), ammonia was the first to be incriminated 
(Eck, 1877)and finds itself still the leading candidate as a key factor in its pathogenesis (Butterworth et al., 1987, 
Butterworth, 1994; Lockwood et al., 1991). Recent studies using Positron Emission Tomography (PET) and 13NH3 
confirm that, in chronic liver failure, brain utilizes ammonia at increased rates and that the blood-brain barrier 
becomes more permeable to ammonia (Lockwood et al., 1991). 
Portal-systemic encephalopathy (PSE) is a common neuropsychiatric disorder resulting from chronic liver disease. 
Clinical features of PSE include impaired mental function, neurological disturbances such as asterixis or flapping 
tremor, and altered states of consciousness progressing to stupor and coma. Multiple PSE episodes are common and 
are associated with precipitating factors such as gastrointestinal bleeding, constipation or sedative use (Sherlock, 
1985). Symptoms of PSE are generally reversible suggesting a metabolic etiology. 
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Ammonia, once taken up by the brain, is transformed into glutamine by glutamine synthetase (GS). However, the 
ammonia-buffering capacity of GS is limited (Butterworth et al., 1988) in chronic liver failure so that brain ammonia 
concentrations rise to attain millimolar concentrations which are deleterious to brain function. Neurochemical 
mechanisms so far proposed to explain the neurotoxic effects of ammonia include direct effects on excitatory and 
inhibitory neurotransmission (Raabe, 1989) and on cerebral energy metabolism (Hindfelt et al., 1977). 
Furthermore, astrocytic uptake of glutamate has been found to be inhibited by high levels of ammonia (Bender and 
Norenberg, 1996) leading to the proposal that PSE may result from glutamatergic synaptic dysregulation 
(Butterworth, 1996). 
Therapeutic strategies aimed at reducing blood and brain ammonia are the mainstay in the prevention and 
treatment of PSE. However, few treatments of hyperammonemic syndromes have so far been designed to counteract 
the molecular actions of ammonia. Clinical studies have shown that L-ornithine-L-aspartate (OA) reduces blood 
ammonia concentrations and improves the clinical symptoms of HE in chronic liver disease (Staedt et al., 1993; 
Kircheis et al., 1997). However, the mechanism responsible for OA's ammonia-lowering action has not been fully 
elucidated. The present study was undertaken to assess the efficacy of OA in the prevention of severe 
encephalopathy precipitated by ammonium acetate treatment of portacaval-shunted rats. The protective effect was 
studied in relation to changes in plasma and CSF amino acids. 
MATERIALS AND METHODS 
O-Phthalaldehyde (OPA) reagent solution, 2-mercaptoethanol and amino acid standards were purchased from 
Sigma Chemical Co., St-Louis, MO; Methanol (HPLC grade), sodium phosphate (monobasic) and tetrahydrofuran 
(THF, HPLC grade) from Anachemia, Montreal, Quebec, Canada. OA was provided by Merz + Co., Frankfurt, Germany. 
All reagents and solvents were of reagent-grade purity unless otherwise stated. Double-distilled deionized water 
was used for preparation of amino acid solutions and buffers. The mobile phase was filtered through 0.45 .|J,m 
filters (Type GS, Millipore Corporation, Bedford, MA) and degassed under vacuum prior to use. 
Portocaval anastomosis (PCA) 
Adult male Sprague-Dawley rats weighing 175-200 g were anesthesized with halothane and an end-to-side PCA was 
performed according to the guidelines of Lee and Fisher (1961). Rats underwent a laparotomy, the inferior vena cava and 
portal vein were isolated allowing the inferior vena cava to be clamped (anastomosis clamp, Roboz Instruments Inc.), 
and the removal of an elliptical piece of vein 1.5 times the portal vein diameter. The portal vein was ligated and cut, 
and an end-to-side anastomosis was performed under a dissecting microscope. Total surgery time was <15 minutes. 
Following surgery, all animals were housed individually with free access to standard laboratory chow and water 
under constant conditions of temperature, humidity, and light cycles. Overall perioperative mortality for shunted 
rats was less than 10%. Four weeks following PCA, rats were pretreated with OA (0.3-1 g/kg body weight/hr, i.v) or 
isotonic saline 6 hours before ammonium acetate (3.85 mmoles/kg body weight, i.p.) to precipitate severe 
reversible neurological signs of encephalopathy. 
Venous and arterial catheters 
Under halothane anesthesia, rats underwent a second laparotomy and two PE-50 catheters were inserted; a venous 
catheter in the vena cava and an arterial catheter in the aorta. Following recovery from anesthesia, a constant OA 
infusion was pumped through the venous catheter and blood samples were collected through the arterial catheter. 
Cisterna magna catheters 
Rats were maintained under isoflurane anesthesia for the duration of the catheter implantation. Cisterna magna 
catheters were installed as previously described (Swain et al., 1992). The animals head was mounted with the skull 
in a horizontal position in a stereotaxic apparatus. A 3 cm incision was made in the skin from the back of the head 
and the overlying connective tissue was removed to expose the skull. A small hole was drilled in the skull using a 
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dental burr (009) on the midline immediately rostral to the interparietal-occipital bone suture. The hole was drilled 
in such a way that the occipital bone could be used as a guideline while inserting the cannula (PE-10 tubing, Clay 
Adams, Parsippany, NJ). The catheter was slowly inserted into the cisterna magna. Correctness of placement of the 
CSF-inflow window was verified by clearing the CSF outway, at which time a spontaneous flow of CSF occured. 
When successful implantation had been confirmed, the skull was cleaned and dried and a small amount of dental 
acrylic cement (Yates and Bird, Chicago, IL) was applied to cover part of the inserted cannula. The whole operation 
took approximately 20 minutes. Rats were housed individually and were allowed to recover from the operation. 
Twenty-four hours after this operation, Silastic tubing (Dow Corning, Midland, MI) was connected to the cannula for 
serial CSF sampling. 
Neurological evaluation 
Following ammonium acetate administration to rats with PCA, a rapidly progressive deterioration of neurological 
status was observed which started with lethargy, progressing to loss of righting reflex and ultimately loss of corneal 
reflex and deep coma, as previously described (Butterworth and Giguere, 1984; Therrien and Butterworth, 1991). 
Measurement of plasma amino acids 
400 μl samples of blood were withdrawn and collected in heparinized micro-tubes just before the start of infusion of 
OA, 1 hour after the start of OA infusion and just prior to the administration of ammonium acetate. A last sample 
was taken from animals from both treatment groups when the saline-treated rats became comatose. Blood samples 
were centrifuged and the plasma was removed, aliquoted and stored at -80°C. 
Amino acids were derivatized with o-phthalaldehyde, separated and analysed using HPLC with fluorescence 
detection according to the method of Spink et al., 1986. Plasma samples were treated with acidified methanol (1:10), 
the mixture was left for 20 minutes at 4°C and centrifuged for 10 minutes at 15,400 g at 4°C. Twelve Ml of the 
supernatant was then withdrawn and mixed with 3 (J.1 of homoserine 0.01 mM as internal standard and reacted at 
room temperature with 20 (M1OPA reagent for 42 seconds, in a total volume of 35M1. Twenty five Ml of this 
solution was then injected onto the HPLC column (C18 Pecosphere, Perkin Elmer) with a CMA/200 autosampler. 
The HPLC system consisted of a solvent delivery system (Perkin Elmer, Series 400) coupled to a fluorometer (Perkin 
Elmer, LC-10 Fluorescence Detector, excitation 370 nm, emission 418-700 nm). Samples were injected in a 50 M1 
loop of a Rheodyne 7125 injector system (Rheodyne, Cotati, CA, U.S.A). Peak area measurements were computed 
using a programmable recording integrator (Perkin-Elmer LC-100). The chromatograph was run with gradients of 
increasing organic solvent concentration generated by differential pumping rates of Solvents A and B. Solvent A 
contained 30 mM disodium phosphate, 30 mM sodium acetate, 2% (v/v) methanol, and 0.05% (w/v) sodium azide 
adjusted to pH 6.2 with glacial acetic acid. Tetrahydrofuran 1% (v/v) was added just before running the system. 
Solvent B consisted of a mixture of water: methanol:acetonitrile:tetrahydrofuran in 19:15:15:1 ratio by volume. 
Each gradient programme ended with a 10 min. hold at 100% solvent B followed by a 5-min reequilibration with 
100% solvent A. Amino acid content of plasma was calculated by peak area analysis using standard curves and the 
internal standard. 
Measurement of CSF amino acids 
Amino acids were analyzed using a Perkin-Elmer reverse phase HPLC system with fluorescence detection and 
precolumn o-phthalaldehyde derivatization as previously described (Therrien and Butterworth, 1991). The HPLC 
system consisted of a solvent delivery system (series 400; Perkin-Elmer; Corwalk, CT) coupled to a filter 
fluorometer (LC-10 fluorescence detector; Perkin-Elmer; excitation at 370 nm, emission at 418-700 nm). Samples 
were injected using a 50 M1 loop of a CMA/200 autosampler with derivatization accessories. The column used was a 
reverse-phase Perkin-Elmer C18.5 m fitted with a Vydec reverse-phase C18 guard column. The chromatogram was 
run with gradients of increasing organic solvent concentration generated by differential pumping rates of solvents A 
and B. Solvent A contained 30 mmol/L sodium phosphate, 30 mmol/L sodium acetate, 2% (vol/vol) methanol, and 
0.05% (w/vol) sodium azide adjusted to pH 6.2 with glacial acetic acid. Tetrahydrofuran 1% (vol/vol) was added 
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just before running the system. Solvent B consisted of a mixture of water:methanol:acetonitrile: tetrahydro-furan in 
19:15:15:1 ratio by volume. Each gradient program ended with a 10-minute hold at 100% solvent B followed by a 
10 minute reequilibration with solvent A. Amino acid content of CSF or brain was calculated by peak area analysis 
using standard curves and the internal standard. 
Measurement of ammonia 
Ammonia concentrations were estimated in plasma using a commercial ammonia test kit, which uses an ion-
exchange method followed by colorimetric measurement of isolated ammonia nitrogen with the Berthelot phenate-
hypochlorate reaction (Dienst, 1961). Ammonia was measured within 24 h of sampling. 
STATISTICAL ANALYSIS 
Data are expressed as mean ± S.E.M. For comparison of data between OA and saline-treated groups, Student-t-tests 
with Bonferroni correction were used. P values of <0.05 were considered to be significant. 
RESULTS 
Protective effect of OA in portacaval-shunted rats administered ammonium acetate 
OA (300 mg/kg/h, i.v for 6 hours) afforded complete protection against ammonia acetate-induced encephalopathy 
in PCS rats. The protective effect observed was highly significant; 12/12 saline-treated PCS controls showed 
deterioration of neurological status progressing to coma whereas none of 12 OA-treated PCS rats showed 
deterioration of neurological status. All rats in the saline-treated control group regained consciousness within 3h of 
ammonium acetateadministration. 
Effects of OA on plasma ammonia in ammonium acetate-treated portacaval-shunted 
rats 
Following ammonium acetate administration, the increase of plasma ammonia was significantly reduced in OA-
treated PCS rats compared to levels in saline-treated PCS rats at all time points (Figure 1). 
 
Figure 1. Protective effect of OA (300 mg/kg/h, i.v) in ammonium acetate-induced coma in portacaval-shunted rats 
in relation to plasma ammonia (left panel) and urea (right panel). Values significantly different from saline-treated 
controls indicated by *p<0.05, **p<0.01. 
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Effects of OA on plasma urea in ammonium acetate-treated portacaval-shunted rats 
Administration of OA to ammonium acetate-treated PCS rats resulted in a significant increase in plasma urea 
(11.56±2.1 mM) compared to saline-treated PCS controls at the coma timepoint (5.91±1.6 mM, p<0.02) (Figure 
1). 
Effects of OA on plasma amino acids in ammonium acetate-treated portacaval-shunted 
rats 
The effects of OA treatment (300 mg/Kg/h) on plasma amino acid concentrations measured at times equivalent to 
those at which saline-treated controls were comatose (ie: had lost their corneal reflexes) are shown in Table 1. 
Table 1. Plasma amino acid concentrations in ammonium acetate-treated, portacaval-shunted rats: Effect of OA 
 
 
 
 
 
 
 
 
 
 
 
 
Values represent mean S.E. of duplicate determination from groups of six rats. *p<0.05 compared to saline-treated 
controls by Student t-test 
 
OA treatment prevented rats from becoming comatose and also resulted in 5-fold increases of alanine (p<0.01), 3-
fold increases in glutamate, glutamine and GABA (p<0.01) and 2-fold increases of the branched chain amino acids 
leucine, isoleucine and valine (p<0.01). Two-fold increases of arginine, aspargine, taurine, threonine and serine 
were also noted after OA treatment. 
Effects of OA on CSF amino acids in ammonium acetate-treated portacaval-shunted 
rats 
In contrast to the effects in plasma, OA treatment resulted in less generalized alterations of amino acids in CSF of 
ammonium acetate-treated portacaval-shunted rats (Table 2). 
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Table 2. Cerebrospinal Fluid Amino Acid Concentrations in Ammonium Acetate-Treatec Portacaval-Shunted Rats: Effect of 
OA 
  
(Legend as in Table 1 ) 
CSF glutamate was increased 3-fold (p<0.01) following OA treatment and significant 30-50% increases of glutamine, 
leucine, alanine and serine were also noted in the CSF of these animals. OA treatment did not result in significant 
alterations of other neuroactive amino acids (aspartate, glycine, GABA, taurine) nor of aromatic amino acids 
(tyrosine, phenylalanine, tryptophan). 
DISCUSSION 
Results of the present study demonstrate a significant protective effect of OA in ammonia-precipitated coma in rats 
following PCA. This finding is consistent with clinical studies in which administration of OA results in decreases in 
plasma ammonia levels and improvement of clinical symptoms in hyperammonemic patients with portal-systemic 
encephalopathy (Kircheis et al., 1997). 
The protective effect of OA in ammonia-induced encephalopathy in shunted rats was accompanied by significant 
reductions in plasma ammonia and a small but significant increase in plasma urea suggesting that the reduction in 
plasma ammonia levels by OA is therefore partly the result of increased urea synthesis in liver; both ornithine and 
aspartate are metabolic substrates for the urea cycle (Figure 2). Increasing the ornithine concentration may 
stimulate flux via ornithine transcarbamylase (OTC) whereas aspartate affords a second nitrogen donor for the 
synthesis of urea. Consistent with increased urea cycle flux are the findings of 2-3-fold increases of plasma arginine 
following OA administration in the present and a previous (Vogels et al., 1995) study . 
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Figure 2. Simplified schematic representation of the urea cycle showing potential points of stimulation of urea cycle 
flux by L-ornithine and L-aspartate. 
Increased urea synthesis by the liver following OA treatment despite the presence of an end-to-side portacaval 
anastomosis is not surprising. A previous study revealed enhanced urea synthesis and a lowering of blood ammonia 
following OA administration to cirrhotic rats (Gebhardt et al., 1997). 
Other potentially benefical actions of L-ornithine and L-aspartate probably involve their ability to cause increased 
glutamate concentrations following stimulation of transaminases (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Displacement  of  transaminase equilibria by OA. OAT: ornithine aminotransferase; AAT: aspartate 
aminotransferase; GSADH: glutamate semialdehyde dehydrogenase. 
Displacement by OA of the ornithine transaminase equilibrium towards glutamate and glutamate semialdehyde 
(and subsequently glutamate by the action of glutamate semialdehyde dehydrogenase, GSADH) and the aspartate 
aminotransferase equilibrium towards glutamate formation potentially affords 3 molecules of glutamate. That such 
mechanisms are operative following OA treatment of PCA shunted rats in the present study is supported by findings 
Rose, C. et al., 1998. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and 
mechanism of action. Metabolic Brain Disease, 13(2), p.147–157. 
The final publication is available at http://dx.doi.org/10.1023/A:1020613314572 
of 3-fold increases of glutamate in body fluids of treated animals (Tables 1,2). The finding of comparable increases 
of glutamate in both plasma and CSF following OA treatment suggests that the above mechanisms (Figure 3) are 
operative both in brain and in peripheral tissues. L-ornithine is a substrate for the G+ transporter at the blood-brain 
barrier (BBB), which is almost completely impermeable to glutamate or aspartate. Increased BBB uptake of L-
ornithine would be expected to result in increased synthesis of glutamate in brain via the transamination reactions 
(Figure 3). 
Increased tissue concentrations of glutamate would then have the potential to stimulate the synthesis of glutamine 
via glutamine synthesis (GS). GS is present in relatively high specific activities in liver, brain and skeletal muscle. 
Furthermore, portacaval shunting results in induction of GS in muscle (Girard and Butterworth, 1992). Given the 
increased availability of enzyme substrate (glutamate) and the possibility of enzyme induction in muscle, it is 
therefore likely that an important mechanism of ammonia-lowering of OA following portacaval shunting involves 
increased glutamine synthesis by skeletal muscle. Additional ammonia removal would also be expected via 
glutamine synthesis in brain. Consistent with these mechanisms are the findings in the present study of significant 
elevations of glutamine in the blood and CSF of OA-treated, portacaval-shunted rats. 
Other potential consequences of increased availability of glutamate would (as expected) include increased GABA 
synthesis (observed in plasma but not in CSF) resulting from increased flux via glutamic acid decarboxylase as well 
as increased synthesis of alanine via pyruvate aminotransferase. Consistent with the latter, alanine concentrations 
were found to be significantly increased both in plasma and CSF of OA-treated animals. In a study of the effects of OA 
on plasma amino acids in patients with cirrhosis, increases in plasma glutamate and alanine were also reported 
(Staedt et al., 1993) suggesting that amino acid changes similar to those observed in the present study occur in 
humans with chronic liver disease following OA treatment. Finally, increased glutamate availability would be 
expected to stimulate branched-chain amino acid (BCAA) aminotransferases resulting in increased synthesis (or 
decreased catabolism) of BCAAs. In favour of this mechanism were the findings in the present study of increased 
plasma concentrations of BCAAs and of leucine in CSF of OA-treated animals. Whether or not increased plasma 
concentrations of BCAAs contributed to the ammonia-lowering effect of OA is unclear. Data from controlled clinical 
trials have yielded equivocal results on the ammonia-lowering capacity of BCAAs (Conn and Eriksson, 1989). 
In summary, results of the present study clearly demonstrate that OA is effective in the prevention of ammonia-
precipitated encephalopathy in portacaval-shunted rats. Findings are consistent with two mechanisms namely: (i) 
increased urea synthesis (albeit at a reduced rate compared to normal animals) and (ii) displacement of multiple 
transaminase reactions giving rise to increased glutamate followed by the facilitation of ammonia removal via 
glutamine synthetase both in peripheral tissues and in brain. Further studies of urea and glutamine synthesis are 
required in order to confirm these possibilities. OA has the potential to lower blood ammonia in ammoniagenic 
conditions associated with chronic liver disease and.in this way, is useful in the prevention of PSE. OA prophylaxis 
could be particularly useful in the prevention of PSE in cirrhotic patients with a history of recurrent gastrointestinal 
bleeding. 
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